The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
Recruiting
N/A
Interventional Study
Acute Normovolemic Hemodilution
Bone Tumor
Goal-Directed Fluid Therapy
Transfusion
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. age 18 to 75 years;
2. undergoing elective bone tumor resection surgery;
3. preoperative hemoglobin ≥11 g/dL;
Exclusion Criteria:
1. using a tourniquet;
2. palliative operation or minimally invasive surgery;
3. BMI\<18.5 or \>30Kg/m\^2;
4. international normalized ratio (IN…
Contacts
No contact information available.